Literature DB >> 16546193

Association of heterozygous familial hypercholesterolemia with smaller HDL particle size.

Jean-Charles Hogue1, Benoît Lamarche, Daniel Gaudet, André J Tremblay, Jean-Pierre Després, Jean Bergeron, Claude Gagné, Patrick Couture.   

Abstract

Small, dense HDL particles have been associated with factors known to increase the risk of cardiovascular disease, such as obesity, hypertriglyceridemia, small dense LDL particles, decreased HDL-cholesterol levels and increased apoA-I fractional catabolic rate from plasma. In order to assess the potential contribution of HDL particle size to atherosclerosis in heterozygous familial hypercholesterolemia (FH), we examined the electrophoretic characteristics of HDL particles in a large cohort of well defined FH heterozygotes and controls. A total of 259 FH heterozygotes and 208 controls participated in the study. FH subjects were carriers of one of the nine French Canadian mutations in the LDL receptor gene. All subjects were apoE3 homozygotes. HDL particles were characterized by non-denaturing polyacrylamide gradient gel electrophoresis following a 6-week lipid-lowering drug-free baseline period. The integrated HDL size was significantly smaller in the FH group compared to controls (FH=87.3+/-5.2 Angstroms versus controls=91.6+/-4.9 Angstroms, P<0.0001). In each groups, men had smaller HDL particles than women. Multiple regression linear analyses showed that the FH/Control status accounted for 20.3% of the variance in the integrated HDL size. These results suggest that the FH/control status was independently associated with variations in HDL particle size and that these variations could contribute to the development of premature atherosclerosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546193     DOI: 10.1016/j.atherosclerosis.2006.02.023

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection.

Authors:  Alexina Orsoni; Samir Saheb; Johannes H M Levels; Geesje Dallinga-Thie; Marielle Atassi; Randa Bittar; Paul Robillard; Eric Bruckert; Anatol Kontush; Alain Carrié; M John Chapman
Journal:  J Lipid Res       Date:  2011-09-26       Impact factor: 5.922

2.  Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.

Authors:  Zahid Ahmad; Beverley Adams-Huet; Chiyuan Chen; Abhimanyu Garg
Journal:  Circ Cardiovasc Genet       Date:  2012-10-11

Review 3.  Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.

Authors:  Joan Carles Escolà-Gil; Noemí Rotllan; Josep Julve; Francisco Blanco-Vaca
Journal:  Curr Atheroscler Rep       Date:  2021-04-29       Impact factor: 5.113

Review 4.  Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2022-07-21       Impact factor: 11.431

5.  ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.

Authors:  Judit Cubedo; Teresa Padró; Rodrigo Alonso; Pedro Mata; Lina Badimon
Journal:  J Lipid Res       Date:  2016-04-25       Impact factor: 5.922

Review 6.  The relationship between high density lipoprotein subclass profile and plasma lipids concentrations.

Authors:  Li Tian; Mingde Fu
Journal:  Lipids Health Dis       Date:  2010-10-17       Impact factor: 3.876

7.  Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia.

Authors:  Bíborka Nádró; Hajnalka Lőrincz; Lilla Juhász; Anita Szentpéteri; Ferenc Sztanek; Éva Varga; Dénes Páll; György Paragh; Mariann Harangi
Journal:  Biomedicines       Date:  2022-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.